One of the challenges with treating children with acute myeloid leukemia is that many of the novel drugs are not available in children. Current treatment with chemotherapy really requires balancing increasing doses with the short-term and long-term toxicities, said Sarah Tasian, MD, attending physician in the Division of Oncology at Children’s Hospital of Philadelphia.
One of the challenges with treating children with acute myeloid leukemia is that many of the novel drugs are not available in children. Current treatment with chemotherapy really requires balancing increasing doses with the short-term and long-term toxicities, said Sarah Tasian, MD, attending physician in the Division of Oncology at Children’s Hospital of Philadelphia.
Transcript
What challenges have there been that have resulted in little improvement in outcomes for children with AML?
I think one of the biggest problems is that there really have not been new drugs for children with AML really in the past 40 years. In the last year, 2 years, there been a lot of new drugs that have been very exciting in terms of small molecule inhibitors or new immunotherapies, but they've largely been restricted to the adult population. And, you know, virtually none of these drugs are actually available to children. So, I think that's been one of the major challenges.
I think the second other major challenges, we have intensified chemotherapy to its maximum limit in our patients, and it has improved outcomes in the past several decades, but we really are to maximal intensity right now, where it's just simply isn't possible to gain any more benefit from you know, higher doses of these drugs. And these drugs are associated with really many short-term and long-term toxicities, both in terms of infection, low blood counts, and a lot of long-term toxicity in terms of children's heart function.
When treating children who have decades left in their lives, how do you balance between treating the cancer but managing long-term toxicities?
I think that's one of the things that's really challenging, as we currently cure about two-thirds of our children now, but some of it comes at very high costs. We currently transplant about a third of our patients in first remission. And that's obviously associated with short growth, sometimes endocrine dysfunction, infertility, which when you have 75 years ahead of you is a major deal.
We also have problems, I think, in particular with cardiotoxicity. We know that giving high doses of anthracycline to our young children is essential for curing them. But when it comes at the expense of you know, reduced cardiac output or even needing a heart transplant later, that seems like too expensive a cost for these therapies.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More